MAPT and Alzheimer disease: Their action through CB1 and CB2 receptors targets multiple pathological processes involved in AD, including beta-amyloid deposition, tau protein phosphorylation, inflammation, mitochondrial dysfunction, and excitatory neurotoxicity.